# Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

> **NCT01896232** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 683 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Chronic Kidney Disease

## Interventions

- **DRUG:** Etelcalcetide
- **DRUG:** Cinacalcet
- **DRUG:** Oral Placebo
- **DRUG:** Intravenous Placebo

## Key facts

- **NCT ID:** NCT01896232
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-13
- **Primary completion:** 2014-11-12
- **Final completion:** 2015-01-08
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896232, "Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01896232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*